tbuckley/cabot-search huggingface dataset:
P-287 Real-world data of perioperative FLOT in resectable gastric and gastro-esophagic junction cancer: The experience of a Portuguese institution
Authors: M. Vilas-Boas, M. Pina, S. Coelho, A. Cruz, M. Silva, A. Rosinha, F. Carneiro, D. Marques, C. Faustino, N. Sousa, P. Ferreira, M. Fragoso
Journal: Annals of Oncology (2022)
SO-6 Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer
Authors: T. Boerner, A. Tin, A. Vickers, C. Harrington, Y. Janjigian, D. Ilson, A. Wu, M. Bott, J. Isbell, B. Park, S. Sihag, D. Jones, R. Downey, A. Shahrokni, D. Molena
Journal: Annals of Oncology (2022)
Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. 2022;82:242–3
Authors: Takeshi Takahashi
Journal: European Urology (2022)
LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Authors: A. Bullock, J. Grossman, M. Fakih, H. Lenz, M. Gordon, K. Margolin, B. Wilky, D. Mahadevan, J. Trent, B. Bockorny, J. Moser, A. Balmanoukian, B. Schlechter, W. Ortuzar Feliu, K. Rosenthal, B. Bullock, J. Stebbing, J. Godwin, S. O'Day, A. Tsimberidou, A. El-Khoueiry
Journal: Annals of Oncology (2022)
SO-7 Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
Authors: Y. Janjigian, S. Rha, D. Oh, M. Díez García, H. van Laarhoven, Y. Chao, M. Di Bartolomeo, N. Haj Mohammad, W. Zhong, E. Croydon, F. Cecchi, J. Lee
Journal: Annals of Oncology (2022)
P-80 A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study
Authors: T. Masuishi, H. Bando, H. Satake, D. Kotani, T. Hamaguchi, M. Shiozawa, T. Ikumoto, Y. Kagawa, H. Yasui, T. Moriwaki, H. Kawakami, S. Boku, E. Oki, Y. Komatsu, H. Taniguchi, K. Muro, M. Kotaka, K. Yamazaki, T. Misumi, T. Yoshino, T. Kato, A. Tsuji
Journal: Annals of Oncology (2022)
P-119 Muscle quantity and quality in metastatic colorectal cancer patients during third-line therapy with regorafenib or TAS102
Authors: C. Maddalena, A. Ponsiglione, L. Camera, L. Santarpia, F. Pasanisi, D. Bruzzese, M. D'Amato, C. Carlomagno
Journal: Annals of Oncology (2022)
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?
Authors: Viviane Cordeiro Veiga, Alexandre Biasi Cavalcanti
Journal: European Respiratory Journal (2022)

Corticosteroids were the first drugs proven to reduce mortality in Covid-19. In June 2020, the RECOVERY group announced the results of their seminal trial showing dexamethasone 6 mg per day was able to reduce 28-day mortality in hospitalized patients with Covid needing supplemental oxygen or mechanical ventilation [1]. Meta-analysis from randomized controlled trials (RCT) in Covid-19 patients confirmed RECOVERY results [2]. In those RCTs, corticosteroid doses were low (dexamethasone 6 mg per day) or intermediate (dexamethasone up to 20mg per day).
A culture model to analyze the acute biomaterial-dependent reaction of human primary neutrophils in vitro
Authors: Marinus A. Wesdorp, Andrea Schwab, Ezgi Irem Bektas, Roberto Narcisi, David Eglin, Martin J. Stoddart, Gerjo J.V.M. Van Osch, Matteo D'Este
Journal: Bioactive Materials (2022)

Neutrophils play a pivotal role in orchestrating the immune system response to biomaterials, the onset and resolution of chronic inflammation, and macrophage polarization. However, the neutrophil response to biomaterials and the consequent impact on tissue engineering approaches is still scarcely understood. Here, we report an in vitro culture model that comprehensively describes the most important neutrophil functions in the light of tissue repair. We isolated human primary neutrophils from peripheral blood and exposed them to a panel of hard, soft, naturally- and synthetically-derived materials. The overall trend showed increased neutrophil survival on naturally derived constructs, together with higher oxidative burst, decreased myeloperoxidase and neutrophil elastase and decreased cytokine secretion compared to neutrophils on synthetic materials. The culture model is a step to better understand the immune modulation elicited by biomaterials. Further studies are needed to correlate the neutrophil response to tissue healing and to elucidate the mechanism triggering the cell response and their consequences in determining inflammation onset and resolution.
P-27 Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer
Authors: T. André, C. Sposetti, M. Gumus, J. Bae Ahn, L. Wyrwicz, M. Kwiatkowski, J. Kim, S. Yalcin, M. Şendur, A. Odeleye-Ajakaye, P. Leconte, D. Fogelman, T. Kim
Journal: Annals of Oncology (2022)
P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
Authors: C. Santos Vivas, F. Salva, C. Fernández-Rodríguez, V. Alonso Orduña, F. Losa, D. Paez, J. Vidal, A. Salud, P. Ribera Fernández, M. Safont Aguilera, N. Tarazona, X. Hernández-Yagüe, L. Layos Romero, R. Garcia-Carbonero, F. Rivera, R. Álvarez Gallego, B. Bellosillo, C. Montagut
Journal: Annals of Oncology (2022)
Effect of asthma management with exhaled nitric oxide<i>versus</i>usual care on perinatal outcomes
Authors: Vanessa E. Murphy, Megan E. Jensen, Elizabeth G. Holliday, Warwick B. Giles, Helen L. Barrett, Leonie K. Callaway, Andrew Bisits, Michael J. Peek, Sean K. Seeho, Alistair Abbott, Annelies L. Robijn, Paul B. Colditz, Andrew Searles, John Attia, Kirsten McCaffery, Michael J. Hensley, Joerg Mattes, Peter G. Gibson
Journal: European Respiratory Journal (2022)

Introduction Asthma exacerbations in pregnancy are associated with adverse perinatal outcomes. We aimed to determine whether fractional exhaled nitric oxide ( F ENO )-based asthma management improves perinatal outcomes compared to usual care. Methods The Breathing for Life Trial was a multicentre, parallel-group, randomised controlled trial conducted in six hospital antenatal clinics, which compared asthma management guided by F ENO (adjustment of asthma treatment according to exhaled nitric oxide and symptoms each 6–12 weeks) to usual care (no treatment adjustment as part of the trial). The primary outcome was a composite of adverse perinatal events (preterm birth, small for gestational age (SGA), perinatal mortality or neonatal hospitalisation) assessed using hospital records. Secondary outcomes included maternal asthma exacerbations. Concealed random allocation, stratified by study site and self-reported smoking status was used, with blinded outcome assessment and statistical analysis (intention to treat). Results Pregnant women with current asthma were recruited; 599 to the control group (608 infants) and 601 to the intervention (615 infants). There were no significant group differences for the primary composite perinatal outcome (152 (25.6%) out of 594 control, 177 (29.4%) out of 603 intervention; OR 1.21, 95% CI 0.94–1.56; p=0.15), preterm birth (OR 1.14, 95% CI 0.78–1.68), SGA (OR 1.06, 95% CI 0.78–1.68), perinatal mortality (OR 3.62, 95% CI 0.80–16.5), neonatal hospitalisation (OR 1.24, 95% CI 0.89–1.72) or maternal asthma exacerbations requiring hospital admission or emergency department presentation (OR 1.19, 95% CI 0.69–2.05). Conclusion F ENO -guided asthma pharmacotherapy delivered by a nurse or midwife in the antenatal clinic setting did not improve perinatal outcomes.
Corneal fibrosis abrogation by a localized AAV-mediated inhibitor of differentiation 3 (Id3) gene therapy in rabbit eyes in vivo
Authors: Suneel Gupta, Michael K Fink, Duraisamy Kempuraj, Nishant R Sinha, Lynn M Martin, Landon M Keele, Prashant R Sinha, Elizabeth A Giuliano, Nathan P Hesemann, Sudhanshu P Raikwar, Shyam S Chaurasia, Rajiv R Mohan
Journal: Molecular Therapy (2022)

Previously we found that inhibitor of differentiation 3 (Id3) gene, a transcriptional repressor, efficiently inhibits corneal keratocyte differentiation to myofibroblasts in vitro. This study evaluated the potential of adeno-associated virus 5 (AAV5)-mediated Id3 gene therapy to treat corneal scarring using an established rabbit in vivo disease model. Corneal scarring/fibrosis in rabbit eyes was induced by alkali trauma, and 24 h thereafter corneas were administered with either balanced salt solution AAV5-naked vector, or AAV5-Id3 vector (n = 6/group) via an optimized reported method. Therapeutic effects of AAV5-Id3 gene therapy on corneal pathology and ocular health were evaluated with clinical, histological, and molecular techniques. Localized AAV5-Id3 gene therapy significantly inhibited corneal fibrosis/haze clinically from 2.7 to 0.7 on the Fantes scale in live animals (AAV5-naked versus AAV5-Id3; p < 0.001). Furthermore, AAV5-Id3 treatment significantly reduced profibrotic gene mRNA levels: α-smooth muscle actin (α-SMA) (2.8-fold; p < 0.001), fibronectin (3.2-fold; p < 0.001), collagen I (0.8-fold; p < 0.001), and collagen III (1.4-fold; p < 0.001), as well as protein levels of α-SMA (23.8%; p < 0.001) and collagens (1.8-fold; p < 0.001). The anti-fibrotic activity of AAV5-Id3 is attributed to reduced myofibroblast formation by disrupting the binding of E-box proteins to the promoter of α-SMA, a transforming growth factor-β signaling downstream target gene. In conclusion, these results indicate that localized AAV5-Id3 delivery in stroma caused no clinically relevant ocular symptoms or corneal cellular toxicity in the rabbit eyes.
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis
Authors: Nicolò Girometti, Ruth Byrne, Margherita Bracchi, Joseph Heskin, Alan McOwan, Victoria Tittle, Keerti Gedela, Christopher Scott, Sheel Patel, Jesal Gohil, Diarmuid Nugent, Tara Suchak, Molly Dickinson, Margaret Feeney, Borja Mora-Peris, Katrina Stegmann, Komal Plaha, Gary Davies, Luke S P Moore, Nabeela Mughal, David Asboe, Marta Boffito, Rachael Jones, Gary Whitlock
Journal: The Lancet Infectious Diseases (2022)
O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials
Authors: E. Martinelli, G. Martini, D. Ciardiello, V. Famiglietti, D. Rossini, C. Antoniotti, T. Troiani, S. Napolitano, L. Esposito, T. Latiano, E. Maiello, M. Del Re, S. Lonardi, G. Aprile, D. Santini, G. Masi, A. Avallone, N. Normanno, F. Pietrantonio, C. Pinto, F. Ciardiello, C. Cremolini
Journal: Annals of Oncology (2022)
P-151 PRO-based symptom management for patients with gastric and esophageal cancer who have undergone previous surgery
Authors: Y. He, S. Wu, C. Ding, L. Fan, L. Ke, Y. Yan, M. Li, H. Luo, X. Hu, J. Niu, H. Li, H. Xu, W. Chen, L. Cao
Journal: Annals of Oncology (2022)
Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality
Authors: Laurens A. van Kleef, Robert J. de Knegt, Willem Pieter Brouwer
Journal: Hepatology (2022)

MAFLD often cooccurs with excessive alcohol consumption, while its prognostic value in this group remains unclear. We aimed to study the mortality risk of MAFLD in relation to excessive alcohol consumption and its potential interactions.We analyzed persons 25-74 years old enrolled in the National Health and Nutrition Examination Survey III cohort with available steatosis and alcohol data. Participants with viral hepatitis, body mass index < 18.5, and missing data on age or follow-up were excluded, leaving 12,656 participants for analysis with a median follow-up of 22.9 [20.9-24.8] years. MAFLD was defined as steatosis on ultrasound in the presence of metabolic dysfunction. Daily alcohol intake of ≥10 g in females and ≥20 g in males was considered excessive alcohol consumption. We quantified mortality risk with multivariate Cox regression for MAFLD and excessive alcohol consumption. Models were adjusted for age, age squared, sex, race, marital status, education, and smoking. MAFLD was present in 31% and excessive alcohol consumption in 13% and were both independently and simultaneously associated with increased mortality risk in fully adjusted models (adjusted HR [aHR], 1.21; 95% CI, 1.13-1.30 and aHR, 1.14; 95% CI, 1.04-1.26, respectively). Similarly, MAFLD was associated with increased mortality risk in participants with and without excessive alcohol consumption. Participants with both MAFLD and excessive alcohol consumption (4.0%) expressed the highest mortality risk (aHR, 1.47; 95% CI, 1.28-1.71). Results were consistent using the initial 10 years of follow-up, a stringent definition of excessive alcohol, and propensity score weighting.MAFLD increases mortality risk independent of excessive alcohol consumption. This underscores the importance of MAFLD, even in patients with excessive alcohol consumption.
Airway autoantibodies are determinants of asthma severity
Authors: Brittany Salter, Nan Zhao, Kiho Son, Nadia Suray Tan, Anna Dvorkin-Gheva, Katherine Radford, Nicola LaVigne, Chynna Huang, Melanie Kjarsgaard, Quan-Zhen Li, Konstantinos Tselios, Hui Fang Lim, Nader Khalidi, Parameswaran Nair, Manali Mukherjee
Journal: European Respiratory Journal (2022)

Local airway autoimmune responses may contribute to steroid dependence and persistent eosinophilia in severe asthma. Auto-IgG antibodies directed against granule proteins such as eosinophil peroxidase (EPX), macrophage scavenger receptor with collagenous structure (MARCO) and nuclear/extranuclear antigens (antinuclear antibodies (ANAs)) have been reported. Our objective was to describe the prevalence and clinical characteristics of asthmatic patients with airway autoreactivity, and to assess if this could be predicted from clinical history of autoreactivity.We analysed anti-EPX, anti-MARCO and ANAs in 218 sputum samples collected prospectively from 148 asthmatic patients, and evaluated their association with lung function parameters, blood/airway inflammation, severity indices and exacerbations. Additionally, 107 of these patients consented to fill out an autoimmune checklist to determine personal/family history of systemic autoimmune disease and symptoms.Out of the 148 patients, 59 (40%) were anti-EPX IgG+, 53 (36%) were anti-MARCO IgG+ and 64 out of 129 (50%) had ≥2 nuclear/extranuclear autoreactivities. A composite airway autoreactivity score (CAAS) demonstrated that 82 patients (55%) had ≥2 airway autoreactivities (considered as CAAS+). Increased airway eosinophil degranulation (OR 15.1, 95% CI 1.1-199.4), increased blood leukocytes (OR 3.5, 95% CI 1.3-10.1) and reduced blood lymphocytes (OR 0.19, 95% CI 0.04-0.84) predicted CAAS+. A third of CAAS+ patients reported an exacerbation, associated with increased anti-EPX and/or anti-MARCO IgG (p<0.05). While no association was found between family history or personal diagnosis of autoimmune disease, 30% of CAAS+ asthmatic patients reported sicca symptoms (p=0.02). Current anti-inflammatory (inhaled/oral corticosteroids and/or adjunct anti-interleukin-5 biologics) treatment does not attenuate airway autoantibodies, irrespective of eosinophil suppression.We report 55% of moderate-severe asthmatic patients to have airway autoreactivity that persists despite anti-inflammatory treatment and is associated with exacerbations.
Corrigendum to “Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft”, [Journal of Control Release, 293 (2019) 183–192]
Authors: Markus Fusser, Anders Øverbye, Abhilash D. Pandya, Ýrr Mørch, Sven Even Borgos, Wanja Kildal, Sofie Snipstad, Einar Sulheim, Karianne Giller Fleten, Hanne Arenberg Askautrud, Olav Engebraaten, Kjersti Flatmark, Tore Geir Iversen, Kirsten Sandvig, Tore Skotland, Gunhild M. Mælandsmo
Journal: Journal of Controlled Release (2022)
P-51 Non-invasive HER2 status diagnosis in gastric cancer using surrogate DNA methylation markers
Authors: X. Liu, G. Ye, X. Lei, H. Li, T. Yang, S. Chen, Y. Yu, X. Chen, G. Zhang, H. Sun, M. Bibikova, C. Cui, Z. Chen, J. Fan
Journal: Annals of Oncology (2022)

Gastric cancer (GC) is the fifth most common and fourth most lethal cancer worldwide. Unlike other cancer types, e.g., lung or breast cancer, very few targeted therapeutics have been developed for GC. HER2 (ERBB2) status is an essential biomarker for guiding the trastuzumab (Herceptin) therapy, which is the only molecularly targeted drug accepted as a first-line therapy, for the treatment of patients with advanced HER2-overexpressing GC. HER2 detection in GC often requires repeated testing to improve the accuracy of the result due to its high degree of heterogeneity. Moreover, HER2 status is dynamic during the clinical course due to genetic differentiation accompanied by neoplastic progression and clonal selection via various factors including chemo- and radiotherapies. Thus, the assessment of HER2 gene copy number in liquid biopsy recently gained a lot of interest for its non-invasiveness, suitability for repeat testing and homogeneity compared to tissue biopsy; however, the limited signal-to-noise ratio (cirdulating tumor DNA (ctDNA) represents a very small fraction in cell-free DNA, which may be less than 0.1%) poses a great challenge for the accuracy and robustness of the tests (either targeted sequencing or droplet digital PCR). Targeted bisulfite sequencing using an enriched panel with pre-selected GC-associated CpG sites was performed on 74 FFPE tissue samples (44 IHC0/1+ and 30 IHC3+) to identify HER2-overexpression-specific methylation markers. Then we verified the performance of these markers for HER2 status determination using methylation-specific quantitative PCR (qMSP) in 71 independent tissue samples, as well as three GC cell lines (N-87 and MKN-7 (Her2+), and MKN-28 (Her2-)). We further validated the performance of the markers on 110 GC plasma samples collected before surgery. A HER2-status diagnostic model was built and the performance was evaluated. We first discovered 105 statistically significant methylation markers for inferring HER2 status in tissue based on the results from targeted sequencing. 69 out of the 105 markers (66%) are located in chromosome 17. qMSP assays were designed for these candidate markers and validated on 110 GC plasma samples. A 3-marker diagnostic model was built and demonstrated sensitivity of 86.7% and specificity of 96.9%, which discriminates HER2-positive from HER2-negative GC patients. The overall plasma-tissue concordance of this liquid biopsy test was 95.5%. Furthermore, the HER2-status test can stratify HER2 IHC2+ patients into either HER2-negative or HER2-positive status, which was confirmed by conventional FISH test. We have developed a novel, accurate and noninvasive qMSP test for determining HER2 status in GC patients. The high concordance with IHC/FISH results of this blood test holds great promise as an auxiliary method to guide HER2-targeted therapy in GC patients.
P-256 Efficacy of FLOT regimen in the Polish population – real-world data from a prospective biomarker study
Authors: K. Marcisz-Grzanka, M. Winiarek, J. Pałucki, P. Wieszczy, T. Olesinski, R. Samsel, U. Sulkowska, A. Kolasinska-Cwikła, M. Jóźwiak, L. Wyrwicz
Journal: Annals of Oncology (2022)
Sickle cell anaemia and severe Plasmodium falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT)
Authors: Sophie Uyoga, Peter Olupot-Olupot, Roisin Connon, Sarah Kiguli, Robert O Opoka, Florence Alaroker, Rita Muhindo, Alexander W Macharia, Arjen M Dondorp, Diana M Gibb, A Sarah Walker, Elizabeth C George, Kathryn Maitland, Thomas N Williams
Journal: The Lancet Child & Adolescent Health (2022)
PD-1 The impact of COVID-19 on diagnosis, stage and treatment of esophageal and gastric cancer
Authors: J. Bakx, B. Doeve, P. Siersema, C. Rosman, N. Grieken, M. van Berge Henegouwen, J. van Sandick, M. Verheij, M. Bijlsma, R. Verhoeven, H. van Laarhoven
Journal: Annals of Oncology (2022)
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy
Authors: Or Kalchiem-Dekel, Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, Lauren A. Kaplanis, Clare Wilhelm, Jordan Eichholz, Guilherme Harada, Lori J. Wirth, Subba R. Digumarthy, Robert P. Lee, David Kadosh, Robin B. Mendelsohn, Jessica Donington, Justin F. Gainor, Alexander Drilon, Jessica J. Lin
Journal: Journal of Thoracic Oncology (2022)
O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
Authors: A. He, J. Valle, C. Lee, M. Ikeda, P. Potemski, C. Morizane, J. Cundom, D. Tougeron, F. Dayyani, N. Rokutanda, J. Xiong, G. Cohen, D. Oh
Journal: Annals of Oncology (2022)
P-168 Combination of gemcitabine plus cisplatin compared to non-gemcitabine and cisplatin regimens as neo-adjuvant treatment in liver transplant recipients with cholangiocarcinoma
Authors: M. Abdelrahim, A. Esmail, J. Xu, G. Umoru, H. Al-Rawi, A. Saharia
Journal: Annals of Oncology (2022)
P-297 Prognostic impact of primary tumor location on synchronous and metachronous colorectal liver metastases: A retrospective monocentric real-life analysis
Authors: C. Signorelli, M. Chilelli, P. Amodio, M. Schirripa, I. Sperduti, R. Santoro, T. Ranalli, G. Pessina, F. Natoni, A. Virtuoso, J. Giron Berrios, M. Mazzotta, F. Nelli, M. Fabbri, F. Primi, E. Marrucci, E. Ruggeri
Journal: Annals of Oncology (2022)
P-97 DNA damage repair (DDR) germline mutations (GMs) in pancreatic ductal adenocarcinoma (PDAC): A mono-institutional retrospective study
Authors: M. Bensi, M. Ribelli, B. Di Stefano, V. Beccia, A. Spring, E. Gurreri, F. Monaca, D. Barone, M. Chiaravalli, M. Maratta, C. Bagalà, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2022)
P-85 Pre-surgical staging and surveillance after curative treatment for pancreatic ductal adenocarcinoma (PDAC): Survey of practice in the United Kingdom (UK)
Authors: A. Lamarca, K. Roberts, J. Graham, H. Kocher, D. Chang, P. Ghaneh, N. Jamieson, D. Propper, J. Bridgewater, T. Ajithkumar, D. Palmer, K. Wedgwood, D. Grose, P. Corrie, J. Valle
Journal: Annals of Oncology (2022)
O-5 Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
Authors: A. Vogel, S. Chan, J. Furuse, W. Tak, G. Masi, M. Varela, J. Kim, S. Tanasanvimon, M. Reig, F. Dayyani, M. Makowsky, M. Marcovitz, A. Negro, G. Abou-Alfa
Journal: Annals of Oncology (2022)
Cardiovascular Disease Risk Among Cancer Survivors
Authors: Roberta Florido, Natalie R. Daya, Chiadi E. Ndumele, Silvia Koton, Stuart D. Russell, Anna Prizment, Roger S. Blumenthal, Kunihiro Matsushita, Yejin Mok, Ashley S. Felix, Josef Coresh, Corinne E. Joshu, Elizabeth A. Platz, Elizabeth Selvin
Journal: Journal of the American College of Cardiology (2022)
SO-10 The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients: Results from the UK MRC OE02 trial
Authors: M. Kloft, M. Nankivell, D. Cunningham, W. Allum, R. Langley, D. Magee, H. Grabsch
Journal: Annals of Oncology (2022)
P-304 Prognostic impact of clinicopathological characteristics on gastrointestinal stromal tumors in a Latin population
Authors: E. Ruiz-Garcia, G. Calderillo-Ruiz, A. Peña-Nieves, C. Diaz, M. Herrera, A. Takahashi, E. Fernandez-Figueroa
Journal: Annals of Oncology (2022)